Tag: psychiatric disorders
University of Sydney spinout bags $273m for psychiatric drug dev’t
Kinoxis Therapeutics, a University of Sydney spinoff, announced a partnership with German pharmaceutical company Boehringer Ingelheim to develop precision therapies that target oxytocin aimed at enhancing the quality of life for people with psychiatric disorders.
Featured Article
Forecasting the future: GridBeyond’s new tool supports smarter energy planning
As Australia’s energy landscape grows more dynamic, businesses operating in the National Electricity Market (NEM) face increasing challenges – from rising costs and evolving regulations to the growing presence of decentralised and renewable energy sources.
